Fox Corporate Team Leads Major MedTech Acquisition

April 25, 2016 – Press Releases

A team of Fox Rothschild LLP corporate attorneys, led by D. William Kaufman, represented NeuWave Medical, Inc., of Madison, Wis., through a major acquisition by Ethicon Endo-Surgery, Inc., a medical device company, which is part of the Johnson & Johnson family of companies.

NeuWave is a privately held medical device company that manufactures and markets minimally invasive soft-tissue microwave ablation systems. Its products, currently used by physicians in more than half of the top cancer centers in the United States, and its mission aligned well with Johnson & Johnson Medical Devices’ strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology.

“This acquisition now provides NeuWave Medical with the ability to accelerate our innovation pipeline and expand the global footprint of our unique technologies, while allowing Ethicon to reach new patients by expanding the availability of a novel intervention that goes beyond surgical options in wide use today,” said Dan Sullivan, the CEO and President of NeuWave Medical in connection with the April 14, 2016, release announcing the transaction.

“Dan Sullivan and I have worked together for nearly three decades and through four M&A deals,” said Kaufman. “I was thrilled to have been able to guide NeuWave through this transaction that will benefit people around the world by making this cutting edge medical technology available to the masses.”

Financial terms of the transaction, which closed on April 13, 2016, have not been disclosed.

Kaufman was assisted on this deal by Fox Rothschild attorneys Phillip B. Martin and Pamela A. Thein. 

For nearly 40 years, Kaufman, a partner with Fox, has worked closely with emerging businesses and venture capital funds to help them realize their business objectives. During the course of his career, he has successfully closed more than 280 venture capital transactions and handled numerous sales of venture-backed companies to large strategic investors. He regularly advises clients on organization selection, equity financing structures, debt financing, technology licenses, domestic and international distribution arrangements, strategic investments, spin-off transactions, clinical trial agreements and M&A transactions.